Florida-based trials contractor Alcanza Clinical Research has acquired San Juan, Puerto Rico-based counterpart FDI Clinical Research.
The deal – financial terms of which were not disclosed – will add a Phase I unit in San Juan as well as a second facility in the west coast city of Mayagüez.
Alcanza CEO Carlos Orantes said “The addition of FDI to the Alcanza site network accelerates our ability to reach more patients who are not traditionally represented with research participation opportunities across a range of increasingly prevalent diseases.
“FDI’s breadth of therapeutic expertise, access to diverse patient populations and ongoing commitment to reducing participation barriers with patient-friendly services will better enable us to deliver on our promise to customers for inclusive research.”
In particular, Orantes cited FDI’s capabilities in endocrine and metabolic conditions, immunology, hepatology, infectious diseases, oncology, respiratory, and rheumatology as attractive additions to its knowledgebase.
These comments were echoed by FDI CEO José Rodríguez-Orengo, who cited the contract research organizations (CROs) access to potential trial participants as an advantage.
“There is tremendous potential for our community-focused research organization to expand locations and support services to offer more opportunities for clinical research as an extension of clinical care. We are excited about the next chapter of our growth with Alcanza.”
At present Alcanza operates a network of 22 research units and several additional sites integrated within specialty clinics at locations across the Southeast, Northeast, and Midwest regions of the US.
FDI is the second addition to Alcanza’s network in a month. On April 9 the firm bought Palmetto Bay, Florida-based Innovation Medical Research Center, a multi-specialty clinical research center.
This deal – financial terms of which were not disclosed - was the ninth acquisition Alcanza has made since 2021. At the time the CRO said the takeover would expand its therapeutic area capabilities and diversity of study participants.
Unsplash/bitontawan02